The TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Unstable Angina/NSTEMI was developed by Antman and colleagues at Brigham and Women's Hospital in 2000, from the TIMI 11B and ESSENCE trial populations (1,957 patients). It was the first widely validated, bedside risk score for the entire spectrum of unstable coronary syndromes and remains the most-cited ACS risk score in the literature. The TIMI UA/NSTEMI score uses seven equally weighted binary variables, each contributing 1 point, to predict the composite endpoint of all-cause mortality, new or recurrent MI, or severe recurrent ischaemia requiring urgent revascularisation at 14 days. It fundamentally changed how emergency physicians and cardiologists approach ACS triage.

The Global Registry of Acute Coronary Events (GRACE) score was developed from a multinational registry of 11,389 patients hospitalised with ACS across 94 hospitals in 14 countries from 1999-2001. Unlike the TIMI score (which uses binary yes/no criteria), GRACE uses continuous variables and weighted regression coefficients to generate a more precise prognostic score. The GRACE score was designed to predict both in-hospital and 6-month post-discharge mortality and has become the preferred ACS risk score in the European Society of Cardiology guidelines. GRACE 2.0 (2014) extended prediction to 1-year and 3-year mortality and removed the creatinine clearance calculation requirement, making it more accessible.

The HEART Score (History, ECG, Age, Risk factors, Troponin) was developed by Six and colleagues in the Netherlands in 2008 and validated by Backus and colleagues in 2010. It was specifically designed for use in the emergency department to rapidly risk-stratify patients presenting with chest pain for major adverse cardiac events (MACE) within 6 weeks. Unlike the TIMI score which was derived from high-risk ACS trial populations, the HEART score was derived from an unselected chest pain population — making it more applicable to general emergency department practice where the majority of patients do not have ACS. The HEART score enables safe early discharge of low-risk patients (score ≤3) without further testing.

The Framingham Risk Score was developed from the landmark Framingham Heart Study — the longest-running cardiovascular cohort study in history, initiated in 1948 in Framingham, Massachusetts with 5,209 men and women. The 10-year CVD risk prediction model was first published by Anderson and colleagues in 1991 and underwent major revisions in 1998 (Wilson et al.) and 2008 (D'Agostino et al.). The Framingham study has produced over 3,000 publications and identified virtually every major cardiovascular risk factor. The 2008 model (using total and HDL cholesterol, systolic BP, BP treatment, diabetes, and smoking) remains the most widely used general CVD risk prediction tool globally, forming the basis for cholesterol and antihypertensive treatment guidelines.

The ACC/AHA Pooled Cohort Equations (PCE) were developed in 2013 by Goff and colleagues as the official cardiovascular risk estimation tool for the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. The PCE were derived from pooling data from multiple large, diverse US cohorts (ARIC, CHS, CARDIA, Framingham Original and Offspring) including 24,626 individuals. Unlike the Framingham score, the PCE were specifically validated in White and African American populations separately and predict a harder cardiovascular endpoint — 10-year risk of first atherosclerotic cardiovascular disease (ASCVD) event, defined as nonfatal MI, coronary heart disease death, or fatal or nonfatal stroke.

The TIMI Risk Score for ST-Elevation Myocardial Infarction (STEMI) was developed by Morrow and colleagues at Brigham and Women's Hospital in 2000, derived from the InTIME II trial of 14,114 STEMI patients treated with fibrinolytic therapy (lanoteplase vs alteplase). It was designed to rapidly stratify 30-day mortality risk in STEMI patients, particularly to identify those who would derive the greatest absolute mortality benefit from aggressive reperfusion therapy. The TIMI STEMI score is a continuous 0-14 point scale using eight variables, all available at the bedside before reperfusion therapy is initiated.

Brain Natriuretic Peptide (BNP) was discovered in 1988 in porcine brain tissue by Sudoh and colleagues, though it is predominantly synthesised and secreted by ventricular cardiomyocytes in response to increased wall stress, volume overload, and elevated filling pressures. BNP and its biologically inactive cleavage product NT-proBNP are the most sensitive and specific biomarkers for heart failure diagnosis in the acute setting. The landmark ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) study (2002) established NT-proBNP as the gold standard for AHF diagnosis, with an AUC of 0.94. BNP and NT-proBNP were subsequently incorporated into ESC 2021, ACC/AHA 2022, and NICE 2018 heart failure guidelines as diagnostic and prognostic cornerstones.

The New York Heart Association (NYHA) Functional Classification was first published in 1928 by the New York Heart Association and has been revised multiple times (1964, 1973, 1994). It is the oldest and most universally used system for quantifying functional limitation due to heart failure, providing a simple 4-class ordinal scale based on physical activity and symptom burden. Despite being entirely subjective and having poor inter-rater reliability (kappa ~0.56), NYHA class has been the primary functional endpoint or stratification variable in virtually every major heart failure clinical trial for nearly a century, including RALES (spironolactone), COPERNICUS (carvedilol), PARADIGM-HF (sacubitril-valsartan), and EMPEROR-Reduced (empagliflozin).

The classification of heart failure by left ventricular ejection fraction (LVEF) has evolved significantly over the past two decades. Originally divided into HFrEF (reduced EF, <40%) and HFpEF (preserved EF, ≥50%), the ESC 2016 guidelines introduced a third category — HFmrEF (mildly reduced EF, 40-49%) — recognising the distinct phenotype and treatment considerations of this intermediate group. The ESC 2021 guidelines further refined this, with LVEF classification now driving four distinct evidence-based treatment pathways. This classification system is fundamental because GDMT benefit is LVEF-dependent — sacubitril-valsartan, CRT, and ICD therapy have only been shown to reduce mortality in HFrEF (LVEF <40%).

Hypertension affects approximately 1.28 billion adults globally and is the single most important preventable cause of premature cardiovascular disease, stroke, and death worldwide. The blood pressure thresholds and treatment targets have been debated extensively, with notable differences between the ACC/AHA 2017 guidelines (≥130/80 mmHg defines Stage 1 hypertension) and the ESC/ESH 2023 guidelines (≥140/90 mmHg for treatment initiation in most patients). The ESC 2023 guidelines represent a major update incorporating the SPRINT (systolic target <120 mmHg) and STEP (elderly Chinese patients) trial data, along with substantial evidence on combination therapy, fixed-dose combinations (FDCs), and SGLT2 inhibitors in hypertensive patients with CKD or HF.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 59 million people globally. Its prevalence doubles with each decade of age after 55. AF-related stroke accounts for approximately 30% of all ischaemic strokes — the majority preventable with anticoagulation guided by CHA₂DS₂-VASc risk stratification. The management of AF has been transformed by three major evidence bases: (1) DOACs (direct oral anticoagulants) replacing warfarin for stroke prevention, (2) catheter ablation becoming first-line rhythm control for symptomatic paroxysmal AF (EARLY-AF, STOP-AF trials), and (3) EAST-AFNET 4 demonstrating mortality benefit of early rhythm control vs rate control in patients with AF <1 year.

The continuity equation for aortic valve area (AVA) is the echocardiographic gold standard for quantifying aortic stenosis severity, derived from the hydrodynamic principle of conservation of mass — stroke volume must be equal at the LVOT and at the aortic valve orifice. Developed as a clinical tool in the 1980s by Hakki and colleagues (simplified formula) and refined by Otto and colleagues, the continuity equation-derived AVA is incorporated into all major AS guidelines as the primary quantitative measure of stenosis severity. Accurate AVA calculation is essential because clinical decision-making (valve replacement timing) is heavily dependent on AVA ≤1.0 cm² as the threshold for severe stenosis.

The Pressure Half-Time (PHT) method for calculating mitral valve area (MVA) was first described by Hatle and colleagues in 1979, based on the principle that the rate of equalisation of pressure between the left atrium and left ventricle during diastole is inversely proportional to the degree of mitral stenosis. The empirical constant 220 (MVA = 220/PHT) was derived from cardiac catheterisation data and validated in early echocardiographic studies. The PHT method is simple, reproducible, and operator-independent compared to the planimetry method — making it the most widely used echocardiographic tool for MVA quantification globally.

Haemodynamic monitoring — measurement of cardiac output, filling pressures, and vascular resistance — forms the foundation of advanced heart failure and critical care cardiology. The pulmonary artery catheter (PAC/Swan-Ganz catheter), introduced by Swan and Ganz in 1970, remains the gold standard for invasive haemodynamic profiling. The Forrester classification (1977) used PCWP and cardiac index to define four haemodynamic profiles in acute MI, which evolved into the Stevenson clinical profiles (warm-dry, warm-wet, cold-dry, cold-wet) used today for ADHF management. Non-invasive estimates using echocardiography (LVOT VTI, IVC collapsibility) have largely replaced PAC in many settings.

The NIH Stroke Scale (NIHSS) was developed by the National Institute of Neurological Disorders and Stroke to provide a standardised, reproducible assessment of neurological deficit severity in acute stroke patients. Originally published in 1989, it has become the global standard for stroke severity quantification, used in clinical trials, treatment eligibility determinations (particularly for IV thrombolysis and mechanical thrombectomy), and outcome prediction. The scale consists of 15 items assessing consciousness, gaze, visual fields, facial palsy, limb motor function, ataxia, sensation, language, dysarthria, and extinction.

The Montreal Cognitive Assessment (MoCA) was developed by Dr. Ziad Nasreddine and colleagues in 1996 as a brief, sensitive screening tool specifically designed to detect mild cognitive impairment (MCI) — a stage often missed by the less sensitive MMSE. The MoCA takes approximately 10 minutes to administer and evaluates eight cognitive domains. It has been translated into over 100 languages and is now the most widely used brief cognitive screening instrument globally, endorsed by major neurology, geriatrics, and dementia societies. It was memorably referenced in public discourse when U.S. President Trump cited his "perfect score" on the test in 2020.

The Mini-Mental State Examination (MMSE) was developed by Folstein, Folstein, and McHugh in 1975 and became the most widely administered cognitive screening instrument in the world, used in over 300 million assessments. It assesses orientation, registration, attention/calculation, recall, and language/visuospatial function. Despite being largely superseded by the MoCA for MCI detection, the MMSE remains in widespread clinical use for tracking dementia severity, monitoring treatment response, and determining decision-making capacity. The MMSE is copyrighted by Psychological Assessment Resources (PAR) and technically requires a license for clinical use.

Glomerular filtration rate (GFR) is the best overall index of kidney function and is used to stage chronic kidney disease (CKD), guide drug dosing, and time renal replacement therapy. The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation was developed in 2009 and updated in 2021 to remove the race coefficient, making it race-free and reducing racial disparities in CKD care. It uses serum creatinine, age, and sex to estimate GFR and is more accurate than the Cockcroft-Gault and MDRD equations, particularly at higher GFR values. The National Kidney Foundation now recommends the 2021 race-free CKD-EPI as the primary equation for CKD staging.

The KDIGO (Kidney Disease: Improving Global Outcomes) AKI staging system was published in 2012 to provide a unified, internationally standardised definition and classification of acute kidney injury. Prior to KDIGO, inconsistent AKI definitions (RIFLE, AKIN) led to challenges in comparing study populations. KDIGO defined AKI as any of: increase in serum creatinine by ≥0.3 mg/dL within 48 hours, increase to ≥1.5× baseline within 7 days, or urine output <0.5 mL/kg/hour for ≥6 hours. Even small creatinine rises (Stage 1) independently predict mortality and hospital length of stay.

The Model for End-Stage Liver Disease (MELD) score was originally developed in 2000 to predict 3-month mortality in patients undergoing TIPS (transjugular intrahepatic portosystemic shunting) procedures, then validated as a superior predictor of waitlist mortality compared to the Child-Pugh score. UNOS adopted MELD for organ allocation in 2002, replacing the Child-Pugh/MELD hybrid system. The score uses three objective laboratory variables: serum bilirubin, international normalised ratio (INR), and serum creatinine — all reflecting different aspects of hepatic and renal function. MELD-Na (incorporating sodium) was adopted by UNOS in 2016 as it better predicts 90-day waitlist mortality.

The Child-Pugh score (originally "Child-Turcotte" classification, later modified by Pugh) was developed in 1964 to assess the prognosis and operative mortality risk in patients with portal hypertension undergoing portosystemic shunt surgery. It incorporates five clinical and laboratory variables: bilirubin, albumin, prothrombin time (or INR), degree of ascites, and degree of hepatic encephalopathy — the latter two being subjective. Despite its age and subjective components, the Child-Pugh score remains clinically relevant and is used in HCC staging (BCLC), drug dosing decisions in liver disease, and assessment of surgical risk.

CURB-65 was developed by the British Thoracic Society (BTS) as a simple, practical tool for assessing severity of community-acquired pneumonia (CAP) and guiding admission decisions. It was derived from a large multicentre UK study and subsequently validated in multiple international cohorts. The score has five equally-weighted components (each 1 point) covering the key prognostic variables in CAP: uraemia, respiratory rate, blood pressure, and age ≥65. Its simplicity makes it one of the most used clinical scores worldwide, though more complex scores like PSI/PORT provide better prognostic granularity.

The Wells Score for Pulmonary Embolism was developed by Dr. Philip Wells and colleagues in 2000 to provide a standardised, reproducible clinical pretest probability assessment for PE, enabling rational use of D-dimer and CT pulmonary angiography (CTPA). Two versions exist: the original "three-tier" (low/moderate/high probability) and the simplified "two-tier" (PE unlikely vs PE likely) version. The score was derived from emergency department cohorts in Canada and subsequently validated in multiple international studies. It is the most widely used PE pretest probability tool, integrated into major diagnostic algorithms (PERC, Christopher, YEARS).

The Sequential Organ Failure Assessment (SOFA) score was developed in 1994 by a European Consensus Group to provide a simple, objective, and continuous measure of organ dysfunction in critically ill patients. Originally called the "Sepsis-related Organ Failure Assessment," it was renamed to reflect its broader application in non-sepsis ICU populations. The score evaluates six organ systems: respiratory (P/F ratio), coagulation (platelets), hepatic (bilirubin), cardiovascular (vasopressor requirement), neurological (GCS), and renal (creatinine/urine output). The Sepsis-3 consensus (2016) incorporated SOFA as a core element of the new sepsis definition.

The Wells DVT Score is a validated clinical decision tool developed by Dr. Philip Wells to stratify pretest probability for deep vein thrombosis (DVT) in outpatients presenting with leg symptoms. It was designed to guide rational use of D-dimer testing and duplex ultrasound, reducing unnecessary imaging. The score incorporates nine clinical variables related to risk factors, examination findings, and alternative diagnoses. It was derived from prospective ED cohort studies and validated in multiple settings internationally.

The Pneumonia Severity Index (PSI), also known as the PORT (Pneumonia Patient Outcomes Research Team) Score, was developed from the Pneumonia Patient Outcomes Research Team study in 1997. It is a 20-variable prognostic scoring system that stratifies patients with community-acquired pneumonia into five risk classes (I-V) based on demographic factors, comorbidities, physical examination findings, and laboratory/radiological data. The PSI is more complex to calculate than CURB-65 but provides superior prognostic accuracy, particularly at the extremes of severity.

Body Mass Index (BMI) was devised by Adolphe Quetelet, a Belgian mathematician, in the 19th century and popularised as a measure of obesity by Ancel Keys in 1972. BMI is calculated as weight (kg) divided by height squared (m²). Despite its widespread use, BMI has significant limitations: it does not distinguish fat mass from lean mass, does not account for fat distribution, and has population-specific validity issues — Asian populations have higher cardiometabolic risk at lower BMI thresholds. The WHO cut-points were set for European populations, and the WHO now recommends lower cut-points for Asian populations (overweight: ≥23 kg/m², obese: ≥27.5 kg/m²).

Quantified bleeding history is a cornerstone of haematological assessment in patients presenting with abnormal bleeding. Bleeding scores systematically capture the severity and number of bleeding symptoms to distinguish normal variation from a true bleeding disorder. The ISTH Bleeding Assessment Tool (ISTH-BAT) was developed by the International Society on Thrombosis and Haemostasis to standardise bleeding history collection and replace inconsistent previous tools. It assigns severity scores (0-4) for 14 bleeding categories and has been validated in von Willebrand disease, platelet function disorders, and other inherited bleeding conditions.

The ECOG Performance Status (PS) scale was developed by the Eastern Cooperative Oncology Group in 1982 as a standardised tool to assess cancer patients' functional capacity and ability to tolerate chemotherapy. It replaced the earlier Karnofsky Performance Scale (KPS) with a simpler 5-point ordinal scale (0-4). ECOG PS is the single most important clinical variable used in oncology trial eligibility, chemotherapy dosing, and treatment decisions. It correlates strongly with overall survival across virtually all cancer types and is used in most prognostic staging systems including IPI, IMDC, R-IPI, and BCLC.

The Glasgow Coma Scale (GCS) was developed by Graham Teasdale and Bryan Jennett at the University of Glasgow in 1974 to provide an objective, standardised method of measuring consciousness in patients with traumatic brain injury. It quickly became the universal standard for neurological observation and is used in trauma, neurosurgery, neurology, and intensive care. The scale assesses three components: eye opening, verbal response, and motor response, with a total score ranging from 3 (deep coma or death) to 15 (fully awake). The Paediatric GCS (pGCS) modifies the verbal and motor components to account for age-appropriate responses in infants and young children.

The Caprini Risk Assessment Model (RAM) was developed by Joseph Caprini, a vascular surgeon, to identify surgical patients at risk for venous thromboembolism (VTE) and guide appropriate prophylaxis. It assigns weighted points to over 40 patient- and surgery-specific risk factors and classifies patients into four risk groups. The Caprini score was validated in multiple large surgical cohorts and is now incorporated into ACCP (American College of Chest Physicians) and ASH guidelines for VTE prophylaxis. High-risk patients (score ≥5) benefit from pharmacological prophylaxis; very high-risk (score ≥9) should continue extended prophylaxis post-discharge.

The Glasgow-Blatchford Score (GBS) was developed by Blatchford and colleagues in 2000 using data from 1,748 patients presenting to a Scottish district general hospital with upper GI bleeding. Unlike the Rockall score, GBS can be calculated entirely at the bedside before endoscopy, using only clinical and basic laboratory variables. Its primary utility is to identify patients at sufficiently low risk (score = 0) to be safely discharged without endoscopy — a powerful triage tool in emergency settings. Multiple studies have shown GBS score of 0 carries a negative predictive value >99% for need for intervention.

The Rockall Score was developed from a large UK national audit of 4,185 cases of acute upper GI bleeding in 1996, making it one of the most rigorously derived scoring systems in gastroenterology. The full post-endoscopy Rockall score incorporates endoscopic findings (diagnosis and stigmata of recent haemorrhage) in addition to clinical parameters, allowing mortality and rebleeding prediction after diagnosis has been established. A pre-endoscopy Rockall score (without endoscopic components) is less accurate but useful for initial risk stratification.

The FIB-4 (Fibrosis-4) Index was originally developed in 2006 by Sterling and colleagues in HIV/HCV co-infected patients at the ACTG A5071 trial, using four simple variables: age, AST, ALT, and platelet count. It was subsequently validated in NAFLD and other chronic liver diseases. The FIB-4 index is the most widely recommended non-invasive test for advanced fibrosis assessment in NAFLD/MASLD, endorsed by the American Association for the Study of Liver Diseases (AASLD), EASL, and the National Lipid Association. It avoids the need for liver biopsy in the majority of patients and is practical in primary care settings.

The AIMS65 score was developed by Saltzman and colleagues in 2011 using data from 29,222 hospitalised patients with acute upper GI bleeding at 187 US hospitals (Premier hospital database). It was designed as an even simpler alternative to the Glasgow-Blatchford Score for predicting in-hospital mortality, length of stay, and cost — all using five variables available at initial presentation. The name AIMS65 is a mnemonic for its components: Albumin, INR, altered Mental Status, Systolic BP, and age ≥65. Its particular strength is predicting in-hospital mortality rather than need for intervention.

The BISAP (Bedside Index for Severity in Acute Pancreatitis) was developed by Wu and colleagues in 2008 from a retrospective analysis of over 18,000 pancreatitis admissions from a national US database. It was specifically designed to be a simple 5-point bedside tool that could predict in-hospital mortality within 24 hours of admission — before CT imaging or 48-hour Ranson's criteria become available. BISAP was validated in a separate cohort of over 16,000 patients, demonstrating comparable discriminatory ability to APACHE-II while being far simpler to calculate. Each point of BISAP approximately doubles mortality risk.

Ranson's Criteria were developed by Dr. John Ranson at New York University in 1974 from a retrospective analysis of 100 patients with acute pancreatitis. The original 11-criteria system (5 measured at admission + 6 at 48 hours) was specifically validated for pancreatitis from any aetiology, with separate criteria for alcoholic pancreatitis. For 50 years, Ranson's Criteria remained the most widely taught and used severity assessment tool in acute pancreatitis — though its 48-hour completion requirement and complexity have led to its gradual replacement by BISAP, APACHE-II, and CT severity index in contemporary practice.

The Harvey-Bradshaw Index (HBI) was published in 1980 as a simplified alternative to the more complex Crohn's Disease Activity Index (CDAI), which requires a 7-day patient diary and haematocrit measurement. The HBI uses five clinical variables assessed on a single day: general wellbeing, abdominal pain, stool frequency, abdominal mass, and extra-intestinal complications. HBI score correlates strongly with CDAI and is used in clinical trials, outpatient monitoring, and clinical decision-making. It is particularly useful in UK/European IBD practice where CDAI is less commonly used.

The Mayo Score for Ulcerative Colitis was developed by Schroeder and colleagues in 1987 as the primary clinical endpoint in the first RCT of oral 5-aminosalicylic acid for mild-to-moderate UC. It rapidly became the most widely used activity index in UC clinical trials and clinical practice. The score incorporates four subscores (stool frequency, rectal bleeding, endoscopic findings, physician's global assessment), each scored 0-3, giving a total of 0-12. The endoscopic subscore is the most objective and correlates best with mucosal healing. The partial Mayo score (without endoscopy, 0-9) is used for outpatient monitoring.

MELD-Na (MELD with Sodium) was developed to address the limitations of the standard MELD score, which underestimates waitlist mortality in cirrhotic patients with hyponatraemia. Hyponatraemia (serum sodium <135 mEq/L) is independently associated with a 2-3× increased risk of 90-day waitlist mortality in cirrhosis. Biggins and colleagues (2006) demonstrated that incorporating serum sodium significantly improved the prognostic accuracy of MELD. UNOS officially adopted MELD-Na for organ allocation in January 2016, replacing standard MELD as the primary allocation score. Serum sodium is capped at 125-137 mEq/L to prevent gaming by aggressive sodium correction.

The Barcelona Clinic Liver Cancer (BCLC) staging system was developed by Llovet, Brú, and Bruix at the Hospital Clínic de Barcelona in 1999. It is the only staging system that simultaneously classifies tumour stage, liver function, and performance status to provide treatment recommendations. BCLC is endorsed by EASL, AASLD, ESMO, and the European Association of Radiology and is used in >90% of HCC clinical trials. The most recent revision (2022) incorporated the BCLC-C subdivision of the intermediate stage and updated systemic therapy options. HCC is the 6th most common cancer worldwide and the 3rd most common cause of cancer-related death.

The International Prognostic Index (IPI) was developed in 1993 by the International Non-Hodgkin's Lymphoma Prognostic Factors Project, a collaborative analysis of 2,031 patients with aggressive NHL treated with CHOP-based regimens. It identified five independent predictors of overall survival and remains the most widely used prognostic tool in lymphoma. The Revised IPI (R-IPI) was developed in 2007 specifically for the rituximab era (R-CHOP), as the original IPI lost its ability to distinguish four separate risk groups when applied to patients treated with R-CHOP — collapsing the original four groups into three more clinically meaningful categories.

The International Metastatic RCC Database Consortium (IMDC) criteria — also known as the Heng criteria after their developer Daniel Heng — were published in 2009, originally derived from 645 mRCC patients treated with VEGF-targeted therapy (sunitinib, sorafenib, or bevacizumab). The IMDC criteria superseded the older Motzer/MSKCC criteria as the standard RCC prognostic model. Critically, the IMDC was validated prospectively in the first-line combination immunotherapy era (CheckMate 214, KEYNOTE-426, CLEAR trials) and remains clinically valid and actionable for first-line treatment selection — IO+TKI combinations are standard for all risk groups, with IO+IO (nivo+ipi) reserved for intermediate/poor-risk patients.

The International Staging System (ISS) for Multiple Myeloma was developed by the International Myeloma Working Group (IMWG) in 2005 from a pooled analysis of 10,750 patients in 17 trials worldwide. It uses only two variables — serum β2-microglobulin and serum albumin — to define three prognostic stages. The Revised ISS (R-ISS) was published in 2015, adding high-risk cytogenetics by FISH (del17p, t4;14, t14;16) and elevated LDH to the ISS to improve prognostic granularity in the era of novel agents (immunomodulatory drugs + proteasome inhibitors). Myeloma diagnosis requires CRAB criteria or biomarkers (SLiM-CRAB) per 2014 IMWG criteria.

The Karnofsky Performance Scale (KPS) was developed by David Karnofsky and Joseph Burchenal at Memorial Sloan Kettering Cancer Center in 1949, making it the oldest and one of the most enduring performance status tools in oncology. Originally designed to assess functional capacity in cancer patients receiving chemotherapy for bronchogenic carcinoma, it uses a 100-point scale in 10-point increments. The KPS was the standard for oncology functional assessment for three decades before the simpler ECOG scale gained widespread adoption. Both scales are used today — KPS is more granular (11 levels vs 5 for ECOG) and is preferred in some subspecialty settings, including glioblastoma management and palliative care.

The Gleason Grading System for prostate cancer was developed by Donald Gleason at the Minneapolis Veterans Affairs Medical Center in the 1960s, with the original description published in 1966. The system assigns a primary pattern grade (most common histological pattern) and secondary pattern grade (second most common), with their sum giving the Gleason score (2-10). The 2005 ISUP consensus and 2014 ISUP revision significantly modernised the system, retiring grades 1-2 in routine reporting and introducing the Grade Group (1-5) system which better predicts clinical behaviour. The WHO 2016 classification formally incorporated Grade Groups as the preferred grading system.

The MASCC (Multinational Association for Supportive Care in Cancer) Risk Index was developed by Klastersky and colleagues in 2000 from a multinational prospective study of 756 febrile neutropenic cancer patients across 15 countries. It was the first validated scoring system to identify febrile neutropenic patients at low risk for serious complications who could be safely managed as outpatients with oral antibiotics — dramatically changing the standard of care from mandatory hospitalisation for all febrile neutropenic patients. The score uses seven clinical variables weighted by their independent contribution to outcome.

The PLASMIC Score was developed by Bendapudi and colleagues at Massachusetts General Hospital in 2017 from a derivation cohort of 112 patients with thrombotic microangiopathy (TMA), then externally validated in 63 patients. It was designed to rapidly identify patients with severe ADAMTS13 deficiency (the hallmark of thrombotic thrombocytopenic purpura) before ADAMTS13 results return — which typically takes 2-5 days. Given that TTP mortality without plasma exchange exceeds 90%, earlier identification and treatment is life-saving. The seven PLASMIC criteria can be evaluated at the bedside from routine blood tests available within hours of presentation.

The International Working Group (IWG) criteria for ITP response assessment were established by Rodeghiero and colleagues in 2009 to standardise the terminology and outcome definitions used in ITP clinical trials and clinical practice — replacing a confusing patchwork of 14 different response criteria used previously. The 2009 IWG guidelines defined complete remission, response, sustained response, and no response using objective platelet count thresholds and treatment-free periods. Immune Thrombocytopenia (ITP) affects approximately 3-5 per 100,000 adults annually, with clinical manifestations ranging from incidental thrombocytopaenia to life-threatening haemorrhage.

The International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes was developed by Greenberg and colleagues in 1997 from a pooled analysis of 816 MDS patients from seven clinical trials. It uses three variables — cytogenetics, bone marrow blast percentage, and number of cytopenias — to stratify patients into four risk groups (Low, Intermediate-1, Intermediate-2, High) with dramatically different survival and AML transformation rates. The IPSS was revised in 2012 (IPSS-R) with improved cytogenetic risk grouping and continuous scoring to provide better prognostic discrimination, particularly in the lower-risk groups. MDS is a clonal stem cell disorder with annual incidence of ~4 per 100,000, predominantly affecting elderly patients.

The Revised International Prognostic Index (R-IPI) for Diffuse Large B-Cell Lymphoma was developed by Sehn and colleagues at the British Columbia Cancer Agency in 2007, in response to the observation that the original IPI (developed in the pre-rituximab era) lost its ability to distinguish four separate risk groups when applied to patients treated with R-CHOP. In the R-CHOP era, original IPI "low-intermediate" and "high-intermediate" risk groups merged into a single outcome group. The R-IPI collapses the five original IPI categories into three clinically meaningful groups (Very Good, Good, Poor) with substantially different 4-year OS and PFS estimates, providing better guidance for treatment intensification decisions.

The Sokal Score for Chronic Myeloid Leukaemia was developed by John Sokal and colleagues in 1984 from a collaborative analysis of 813 CML patients treated with busulphan or hydroxyurea (the pre-TKI era). Despite being developed over 40 years ago, the Sokal score retains prognostic value in the TKI era and is recommended by the European LeukemiaNet (ELN) 2020 guidelines for initial risk stratification of newly diagnosed CML. Patients with high Sokal scores achieve lower rates of deep molecular response (MR4/MR4.5) with imatinib and are more likely to require 2nd-generation TKIs. The Sokal formula uses age, spleen size, platelet count, and peripheral blood blast percentage.

The Dynamic International Prognostic Scoring System (DIPSS) for myelofibrosis was developed by Passamonti and colleagues in 2010 as a dynamic improvement over the original IPSS (which only used presentation data). DIPSS uses the same five risk factors as IPSS but weights anaemia (Hgb <10 g/dL) twice, reflecting its stronger prognostic impact discovered in follow-up analyses. DIPSS can be applied at any time during the disease course, not just at diagnosis — making it "dynamic." DIPSS-Plus (2011) added three additional independent adverse factors (platelet count <100, unfavourable karyotype, transfusion need) for further refinement. Primary myelofibrosis (PMF) has an annual incidence of ~0.5-1.5 per 100,000, predominantly affecting patients aged 60-70.

The ISTH Bleeding Assessment Tool (ISTH-BAT) was developed in 2010 by the Scientific and Standardisation Committee (SSC) of the International Society on Thrombosis and Haemostasis to provide a standardised, validated instrument for quantifying bleeding history in patients suspected of having inherited bleeding disorders. Before the ISTH-BAT, at least five different bleeding questionnaires were in use, making it impossible to compare data across centres and studies. The ISTH-BAT assigns severity scores (0-4) for each of 14 bleeding symptoms and calculates a total bleeding score (BS). An abnormal BS (>3 in males or >5 in females) has been validated as predictive of von Willebrand disease, platelet function disorders, and other inherited bleeding conditions.

Antiphospholipid Syndrome (APS) is an acquired autoimmune thrombophilia characterised by persistent antiphospholipid antibodies (aPL) causing arterial/venous thrombosis and/or obstetric complications. The Sapporo criteria (1998), revised as the Sydney criteria (2006), established the international consensus definition requiring at least one clinical criterion (thrombosis or pregnancy morbidity) and one laboratory criterion (LA, aCL, or anti-β2GPI positive on two occasions ≥12 weeks apart). The triple-positive profile (all three antibodies positive) confers the highest thrombotic recurrence risk and is a key driver of treatment decisions — warranting warfarin over DOACs based on multiple randomised trials demonstrating DOAC inferiority in this group.

Visual acuity (VA) is the most fundamental measure of visual function, quantifying the spatial resolving power of the eye. It is expressed in multiple formats worldwide: Snellen fractions (20/20 in the US; 6/6 in the UK/metric), decimal notation, logMAR (logarithm of the Minimum Angle of Resolution), and percentage of normal. The logMAR scale is the gold standard in research and low vision clinics because it provides a linear scale where equal steps represent equal changes in resolution, unlike the non-linear Snellen fraction. The minimum angle of resolution (MAR) defines the smallest detail a patient can see. At VA 20/20 (6/6), the MAR = 1 arcminute. At 20/200, MAR = 10 arcminutes. logMAR = log₁₀(MAR), so 20/20 = logMAR 0.0, 20/200 = logMAR 1.0. ETDRS charts (Early Treatment Diabetic Retinopathy Study) use 5 letters per line with 0.1 logMAR steps, providing standardised scoring across trials. The WHO graded visual impairment from Grade 0 (normal, ≥6/18) through Grade 5 (no light perception), with Grade 3+ constituting blindness by international definition (VA <3/60 or VF <10°).

Age-related macular degeneration (AMD) is the leading cause of irreversible severe vision loss in adults over 55 in the developed world. It progresses through early AMD (small-medium drusen, no pigment changes), intermediate AMD (large drusen ≥125μm or multiple medium drusen, ± pigment changes), and advanced AMD (geographic atrophy or neovascular/wet AMD with choroidal neovascularisation, CNV). The AREDS (Age-Related Eye Disease Study) and AREDS2 trials were landmark NIH-funded studies establishing the role of antioxidant supplementation in reducing progression to advanced AMD. AREDS2 (2013) refined the original formula by replacing beta-carotene with lutein (10mg) and zeaxanthin (2mg) — avoiding the lung cancer risk in smokers — and optimised zinc dose. The AREDS2 simplified severity scale assigns 0-4 points based on large drusen and pigment abnormality per eye, providing a clinically practical 5-year risk estimate. Anti-VEGF agents (ranibizumab, aflibercept, brolucizumab, faricimab) have transformed the treatment of neovascular AMD, with treat-and-extend protocols now the standard of care. Geographic atrophy treatment gained FDA approval in 2023 (pegcetacoplan / avacincaptad pegol), representing a new era for the dry AMD end-stage.

Ocular hypertension (OHT), defined as IOP >21 mmHg without glaucomatous optic nerve damage or visual field loss, affects approximately 3-5% of the adult population over 40. Without treatment, ~10% per year of OHT patients develop primary open-angle glaucoma (POAG). The OHTS trial (published 2002) was the landmark RCT demonstrating that topical IOP-lowering therapy halved the 5-year conversion rate from OHT to POAG (from 9.5% to 4.4%). The OHTS/EGPS risk model identifies five independent predictors: IOP, CCT (central corneal thickness), vertical cup-to-disc ratio, VF pattern standard deviation, and age. Notably, the presence of diabetes mellitus was associated with slightly lower conversion risk in OHTS — possibly due to protective effects of advanced glycation on the trabecular meshwork or ascertainment bias. This counterintuitive finding is preserved in the risk model. CCT is crucial: eyes with thin corneas (<520 μm) are at higher glaucoma risk and also may have IOP underestimated by Goldmann applanation tonometry. The OHTS model uses these factors to guide the decision between observation and treatment initiation.

The optic disc is the site where retinal ganglion cell axons exit the eye as the optic nerve. The neuroretinal rim (NRR) consists of the neural tissue around the central cup. In glaucoma, progressive loss of retinal ganglion cells results in rim thinning, cup enlargement, and eventually characteristic notching and field loss. The cup-to-disc ratio (CDR) is the simplest and most widely used measure of disc excavation. The ISNT rule (Inferior > Superior > Nasal > Temporal rim width) describes the normal relative thickness of the neuroretinal rim in each quadrant. Violation of the ISNT rule — particularly inferior or superior notching — is an early indicator of glaucomatous damage, preceding detectable visual field loss in many patients. The neuroretinal rim area correlates with the number of surviving ganglion cell axons. Asymmetry of CDR between the two eyes ≥0.2 is considered suspicious regardless of the absolute CDR value, as physiological cups are usually symmetric. OCT of the retinal nerve fibre layer (RNFL) provides objective, quantitative measurement that complements clinical disc assessment.

Dry Eye Disease (DED) is one of the most prevalent ocular conditions worldwide, affecting an estimated 5-50% of the population depending on diagnostic criteria and geography — higher in Asian populations and menopausal women. The Tear Film & Ocular Surface Society (TFOS) DEWS II (2017) redefined DED as "a multifactorial disease of the ocular surface characterised by loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play aetiological roles." The two major subtypes — aqueous deficient (AD-DED, reduced Schirmer, associated with Sjögren syndrome) and evaporative DED (EV-DED, most common, associated with meibomian gland dysfunction, MGD) — often overlap. Meibomian gland dysfunction is present in over 80% of DED cases and is driven by posterior lid disease, resulting in abnormal lipid layer and rapid tear evaporation. TFOS DEWS II provides a 4-step treatment ladder from lubricants and lifestyle modification (Step 1) through anti-inflammatory therapy (Step 2-3) to surgical intervention (Step 4). Cyclosporine A (Restasis), lifitegrast (Xiidra), and oral secretagogues form the pharmacological backbone of moderate-severe disease.

Keratoconus is a bilateral but often asymmetric ectatic corneal disorder characterised by progressive stromal thinning, conical protrusion, and irregular astigmatism, resulting in progressive visual impairment. It typically manifests in the second decade of life, progresses until the third or fourth decade, then stabilises. Prevalence is approximately 1 in 2,000 in the general population, with higher rates in certain ethnicities (South Asian, Middle Eastern populations). The Amsler-Krumeich classification (1995) is the most widely used clinical staging system, grading keratoconus from Stage I (mild, treatable with glasses) through Stage IV (severe, requiring penetrating keratoplasty). It uses keratometry readings, refractive error magnitude, central corneal thickness, and the presence of corneal scarring. Corneal cross-linking (CXL — riboflavin/UV-A collagen crosslinking, Dresden protocol) is the only treatment that halts keratoconus progression and has become standard of care for documented progressive keratoconus. The CAIRS trial (2022) showed equivalent outcomes with accelerated CXL at 9 mW/cm². Scleral lenses have transformed the quality of life for advanced keratoconus patients by vaulting over the irregular cornea.

The Humphrey Visual Field Analyser (HFA) using the 24-2 SITA Standard algorithm is the gold standard for detecting and monitoring glaucomatous visual field loss in clinical practice. The 24-2 pattern tests 54 points within the central 24° radius, with test locations optimised for glaucoma detection based on the retinal nerve fibre layer distribution. The Hodapp-Parrish-Anderson (HPA) severity criteria (1993) provide a practical three-tier classification (early, moderate, severe) based on Mean Deviation (MD), Pattern Standard Deviation (PSD), and the number and location of significantly depressed test points. MD reflects the overall sensitivity loss compared to an age-matched normal population; PSD reflects localised (pattern) loss relative to the patient's own hill of vision — making it more sensitive for early focal glaucomatous defects. Visual field progression assessment has evolved from purely statistical analysis (Linear regression, event analysis) to the validated Guided Progression Analysis (GPA) in Humphrey software, which flags 3 confirmed progressively worsening points. Rate of MD change of >1 dB/year is considered clinically significant progression.

Refractive errors — myopia, hyperopia, and astigmatism — are the most common cause of correctable vision impairment worldwide, affecting an estimated 2.6 billion people with myopia alone. The global prevalence of myopia has increased dramatically over the past 50 years, driven primarily by reduced outdoor time and increased near-work, particularly in East Asia where prevalence in young adults exceeds 80-90%. The International Myopia Institute (IMI) 2019 white papers established internationally agreed definitions: myopia as spherical equivalent ≤-0.5D; high myopia as ≤-5.0D or -6.0D (varying by context); pathological myopia as myopia with associated structural complications (myopic maculopathy, posterior staphyloma, foveoschisis, myopic CNV). High myopia carries substantially elevated risks of retinal detachment, glaucoma, macular degeneration, and cataract — consequences that accumulate over a lifetime. Myopia control interventions with evidence include: atropine 0.05% (LAMP2 trial), orthokeratology (overnight contact lenses), high-add soft contact lenses (MiSight), and increased outdoor time (minimum 1-2 hours/day). These modalities slow axial elongation by 40-60%, representing a paradigm shift from correction to prevention.

Primary angle-closure glaucoma (PACG) is particularly prevalent in East and South Asian populations, accounting for nearly half of all glaucoma blindness worldwide despite representing only ~25% of glaucoma cases. It is characterised by anatomical predisposition (shorter axial length, shallower anterior chamber, thicker, more anteriorly positioned lens) that results in relative pupil block, iris bowing, and peripheral anterior synechiae obstructing the trabecular meshwork. The Van Herick technique (1969) is the most widely used screening method for estimating peripheral anterior chamber depth (PACD) using a slit lamp. It compares the width of the dark space between the corneal endothelium and iris surface against the corneal optical section thickness (PCT) using a temporal parallelepiped beam. A ratio <1/4 (Grade 1-2) predicts occludable angles in most cases and indicates gonioscopy and possible prophylactic laser peripheral iridotomy (LPI). Prophylactic LPI has been standard of care for Grade 1-2 angles for decades. However, the EAGLE trial (2016) found LPI superior to observation for PACS (primary angle-closure suspects) in Asian populations in terms of cost-effectiveness and patient-reported outcomes. The ZAP trial (2019) showed no significant IOP benefit of LPI vs observation in Chinese PACS patients at 6 years — ongoing debate refining LPI indications.

Rhegmatogenous retinal detachment (RRD) occurs when a retinal break allows vitreous fluid to accumulate in the subretinal space, separating the sensory retina from the retinal pigment epithelium. It is the most common sight-threatening emergency in ophthalmology, with an incidence of approximately 1 in 10,000 per year in the general population. Risk is substantially elevated in myopes (3-8x), those with posterior vitreous detachment (PVD), and those with peripheral retinal pathology. Posterior vitreous detachment (PVD) is the initiating event in most RRDs, occurring in ~75% of adults over 65. As the vitreous collagen gel liquefies and collapses, the cortical vitreous detaches from the inner limiting membrane. If vitreoretinal adhesions are present, tractional forces can cause retinal tears — particularly horseshoe (flap) tears which have high detachment potential (~25-50% without treatment). New floaters and photopsia with a symptomatic PVD require dilated fundus examination within 24 hours. Symptomatic horseshoe tears carry ~30-50% risk of progressing to detachment; atrophic holes carry much lower risk (~1-3%). Prophylactic laser retinopexy for symptomatic horseshoe tears reduces the risk of RRD by ~90%. Treatment of established RRD includes pneumatic retinopexy (selected cases), scleral buckling, or pars plana vitrectomy.

Colour vision deficiency (CVD) affects approximately 8% of males and 0.5% of females of Northern European descent, making it one of the most common genetic conditions. The X-linked inheritance pattern explains the sex disparity. Congenital CVD results from mutations in the OPN1LW (L-cone / red) or OPN1MW (M-cone / green) photoreceptor genes, with red-green defects (protanopia/deuteranopia and their partial forms protanomaly/deuteranomaly) comprising >99% of congenital cases. The Ishihara pseudoisochromatic plates (1917, 24 or 38 plate editions) are the global standard for screening red-green CVD. The 14-plate screening edition is most commonly used clinically: ≥13/14 = normal colour vision; ≤12/14 = CVD present. Ishihara is sensitive for R-G defects but does NOT detect tritan (blue-yellow) defects or accurately quantify severity. The Farnsworth D-15 and Farnsworth-Munsell 100-hue tests provide grading and axis determination. Acquired CVD should raise suspicion for optic nerve or macular disease. Tritan (blue-yellow) defects suggest glaucoma, diabetic retinopathy, or toxic optic neuropathy. Asymmetric CVD between the two eyes is almost always acquired and warrants investigation. Optic neuritis (MS) characteristically causes acquired red desaturation and reduced colour contrast.

Strabismus (ocular misalignment) affects approximately 3-5% of the population and can cause amblyopia, diplopia, loss of stereopsis, and significant psychosocial impact. Management involves a combination of optical correction (prisms or glasses), patching for amblyopia, botulinum toxin injection, and surgical muscle correction depending on the aetiology, deviation type, and magnitude. Prisms deviate light, allowing a misaligned eye to see the same image as the fellow eye without requiring motor fusion — providing relief from diplopia without surgery. Prism power is measured in prism dioptres (Δ), where 1 prism dioptre deviates a beam 1 cm at 1 metre. Prentice's Rule defines induced prism: P = c × F (decentration in cm × lens power in dioptres). Fresnel press-on prisms (vinyl membrane) are used for large deviations, trials, or unstable deviations because they can be easily changed and applied to existing spectacle lenses. However, they reduce optical quality significantly. Ground-in prisms are incorporated into spectacle lenses for smaller stable deviations (usually ≤12Δ per lens). The ⅔ rule applies to decompensating phorias, where full prism correction may lead to adaptation and worsening deviation.

Total PSA alone in the grey zone of 4–10 ng/mL has a specificity of only ~25% for prostate cancer, meaning ~75% of biopsies in this range are negative. The free-to-total PSA ratio (%fPSA) exploits the observation that prostate cancer cells produce a higher proportion of complexed PSA (bound to ACT, API) while BPH produces more free PSA. A low %fPSA therefore reflects the cancer pattern of PSA complexation. Catalona's landmark 1998 JAMA study demonstrated that using a %fPSA threshold of 25% could detect 95% of cancers while avoiding 20% of unnecessary biopsies. Lower thresholds (<10%) identify the highest-risk group (~56% cancer probability). The %fPSA is most informative when total PSA is in the 4–10 ng/mL range ("grey zone") — below 4, it adds little; above 10, biopsy is already strongly indicated. Important caveats: %fPSA is unreliable after ejaculation (<48 h), vigorous cycling, prostatitis, or 5-ARI therapy (which raises %fPSA). Free PSA is less stable than total PSA and degrades rapidly — samples must be refrigerated and processed promptly.

Erectile dysfunction (ED) affects an estimated 150 million men worldwide, with prevalence increasing with age — 40% at age 40, rising to ~70% by age 70. The International Index of Erectile Function (IIEF) was developed by Rosen et al. (1997) as a 15-item psychometrically validated instrument for ED assessment. The abbreviated 5-item version (IIEF-5, also called SHIM — Sexual Health Inventory for Men) was developed in 1999 and provides excellent sensitivity (98%) and specificity (88%) for ED diagnosis. ED shares vascular, metabolic, and neurological risk factors with cardiovascular disease. ED often precedes symptomatic cardiovascular disease by 3–5 years, making it a useful window for cardiovascular risk assessment — particularly in men aged 40–60. The Princeton III Consensus (2012) updated cardiovascular risk stratification for men with ED initiating PDE5 inhibitors. Phosphodiesterase type 5 inhibitors (PDE5i) — sildenafil, tadalafil, vardenafil, avanafil — are first-line pharmacotherapy for most organic and mixed ED, achieving satisfactory erections in 60–70% of men. Tadalafil 5 mg daily (approved 2003) provides on-demand flexibility and also treats LUTS/BPH. Low-intensity shockwave therapy (LiSWT) has emerging RCT evidence for vasculogenic ED.

The Gleason grading system, introduced by Donald Gleason in 1966, grades prostate cancer based on its glandular architecture under low magnification (patterns 1–5). The combined Gleason score (primary + secondary pattern) was the standard for decades. The 2005 ISUP consensus modified Gleason scoring — eliminating Patterns 1 and 2 on biopsy, mandating pattern 4 quantification, and incorporating tertiary pattern 5. The Grade Group (GG) system was introduced by Epstein et al. in 2014 and adopted by ISUP/WHO in 2016 to address limitations of the Gleason score: the fact that Gleason 6 (GG1) is the lowest score ever assigned on biopsy, making patients believe they have a "6 out of 10" cancer. Grade Groups 1–5 provide a more intuitive hierarchy, with GG1 carrying essentially zero metastatic potential and GG5 (Gleason 9–10) carrying very high risk. Cancer-specific 10-year mortality by grade group: GG1 ~1%, GG2 ~3%, GG3 ~6%, GG4 ~15%, GG5 ~30–40%. These figures underscore the importance of accurate grading for treatment decision-making. The ISUP 2019 consensus provided updates on cribriform pattern 4 (adverse prognosis), intraductal carcinoma (IDC), and small cell/neuroendocrine carcinoma classification.

Kidney stone disease affects approximately 12% of men and 6% of women in their lifetime, with a 5-year recurrence rate of approximately 50% after a first stone episode. Recurrence rates vary dramatically by stone type: uric acid stones have near 100% recurrence without treatment, cystinuria is a lifelong metabolic disorder with constant stone-forming tendency, while idiopathic calcium oxalate stones have more variable recurrence. The ROKS (Recurrence Of Kidney Stone) nomogram was developed to provide individualised 5-year recurrence probability for first-time stone formers to guide the intensity of preventive efforts and follow-up. Key predictors include patient age, sex, stone composition, family history, number of stones at presentation, and BMI. Metabolic evaluation with 24-hour urine collection is the cornerstone of secondary prevention, identifying specific metabolic abnormalities (hypercalciuria, hyperoxaluria, hypocitraturia, hyperuricosuria) that can be targeted with dietary modification and pharmacotherapy. The PRSNE study demonstrated that intensive metabolic management reduced recurrence from 50% to ~25% at 5 years.

Understanding the relationship between urinary pH and stone composition is fundamental to preventive urology. Urine pH is tightly regulated by the kidney and reflects systemic acid-base status, diet, renal tubular function, and infection. Different stone types form under distinct urinary chemical environments, making the fresh urine pH a powerful clinical clue to stone type in the absence of stone analysis. Uric acid stones form almost exclusively in persistently acidic urine (pH <5.5), driven by insulin resistance-mediated decrease in renal ammoniagenesis, which forces acid excretion as titratable acid rather than ammonium. This makes uric acid stones unique in their complete dissolvability with urinary alkalinisation — the only stone type amenable to medical dissolution. Struvite stones require urease-producing bacteria (Proteus, Klebsiella, Pseudomonas) that alkalinise urine above pH 7.0 by converting urea to ammonia and bicarbonate. Calcium phosphate stones (brushite, hydroxyapatite) also form in alkaline urine, often associated with primary hyperparathyroidism, renal tubular acidosis (RTA), or high-dose calcium and vitamin D supplementation. Calcium oxalate, the most common stone type, is relatively pH-independent but forms optimally at neutral-mildly acidic pH.

Testicular volume is a clinically important measure in three main contexts: puberty staging in adolescents, fertility assessment and hypogonadism evaluation in adults, and varicocele monitoring. The testicle is the site of spermatogenesis (seminiferous tubules, ~80% of volume) and steroidogenesis (Leydig cells, ~10% of volume). Volume reflects the mass of functional spermatogenic tissue, making it a proxy for spermatogenic potential. Pubertal onset in males is defined by testicular enlargement to ≥4 mL (Prader orchidometer), typically occurring between ages 9 and 14. The Prader orchidometer uses a series of ellipsoid beads to estimate testicular volume by comparison, and remains the clinical standard despite overestimating volume by 20–30% vs ultrasound. The Lambert ellipsoid formula (V = 0.71 × L × W × H) better approximates TRUS-measured volumes than the classic π/6 formula. In fertility workup, testicular atrophy (volume <15 mL bilateral or <12 mL with abnormal semen analysis) is strongly associated with spermatogenic failure. Klinefelter syndrome (47,XXY) — affecting ~1 in 650 males — presents with small firm testes (<6 mL), azoospermia, elevated FSH, and often tall stature. Varicocele causes left testicular hypotrophy in ~70% of affected men and responds to varicocelectomy with catch-up growth in adolescents.

Overactive bladder (OAB) is defined by the ICS as "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence (UUI), in the absence of UTI or other obvious pathology." It affects an estimated 12–17% of adults worldwide, with prevalence increasing with age. OAB-wet (with UUI) is present in ~30–40% of OAB patients and has greater quality-of-life impact. The OAB-V8 (Overactive Bladder Validated 8) questionnaire was developed to screen for OAB in primary care and specialist settings. It was validated against urodynamic diagnoses and other validated questionnaires. A score ≥8 has sensitivity of 68% and specificity of 79% for OAB diagnosis. The primary symptom driving OAB diagnosis is urgency — the hallmark symptom distinguishing OAB from stress urinary incontinence and other lower urinary tract disorders. First-line management is behavioural therapy (bladder training, PFMT), which achieves 50–80% symptom improvement in RCTs. Pharmacological therapy with antimuscarinics (solifenacin preferred) or beta-3 agonist (mirabegron) are second-line. Third-line interventions include posterior tibial nerve stimulation, onabotulinumtoxinA injection, and sacral neuromodulation — all with evidence for refractory OAB.

Non-muscle invasive bladder cancer (NMIBC) — Ta, T1, and carcinoma in situ (CIS) — accounts for approximately 75% of all new bladder cancer diagnoses. While NMIBC is not life-threatening in its initial presentation, it carries a substantial burden of recurrence (50–70% at 5 years) and progression to muscle-invasive disease (10–30% depending on risk category). Recurrence requires repeated cystoscopic surveillance and transurethral resection, making bladder cancer the most expensive cancer per patient in terms of cumulative lifetime cost. The EORTC risk tables (Sylvester et al., 2006) were derived from a pooled analysis of 7 EORTC trials involving 2,596 patients and provide 1-year and 5-year recurrence and progression probabilities based on six clinical and pathological variables. The CUETO scoring model (Fernandez-Gomez et al., 2009) provides an alternative validated in BCG-treated patients specifically. Intravesical BCG (Bacillus Calmette-Guérin) remains the most effective adjuvant treatment for intermediate and high-risk NMIBC, reducing recurrence by 44% and progression by 37% in meta-analyses. BCG-unresponsive disease — defined as failure to achieve disease-free status by 6 months after adequate BCG — carries a poor prognosis with bladder-sparing approaches and radical cystectomy should be strongly considered.

Testicular torsion is a urological emergency caused by rotation of the testicle on the spermatic cord, resulting in progressive ischaemia and infarction if untreated. It affects approximately 1 in 4,000 males annually, with bimodal peaks in the neonatal period and peripubertal period (ages 12–18). The bell-clapper deformity — a congenital abnormality in which the tunica vaginalis incompletely attaches to the posterior testicle, allowing free rotation — is present bilaterally in ~80% of affected patients. The diagnosis is primarily clinical, and salvage rates are directly related to time from symptom onset to surgical detorsion: >90% salvage within 6 hours, ~50% at 6–12 hours, and <10% after 24 hours. High clinical suspicion warrants immediate surgical exploration without waiting for Doppler ultrasound — imaging should never delay surgery in a high-probability case. The TWIST (Testicular Workup for Ischaemia and Suspected Torsion) score was prospectively validated by Barbosa et al. (2013) to stratify risk and guide immediate versus imaging-guided management. A TWIST score ≥5 has sensitivity 76% and specificity 100% for torsion, warranting immediate exploration without ultrasound. Scores ≤2 can safely undergo ultrasound evaluation first.

Accurate prostate volume measurement is essential for PSA density calculation, BPH treatment planning, and 5-alpha reductase inhibitor therapy optimisation. The prostate gland is triaxially asymmetric, making the prolate ellipsoid formula (V = π/6 × L × W × H ≈ 0.523 × L × W × H) the most practical approximation for clinical use. The formula consistently underestimates volume by 5–10% compared to planimetric measurement, but this is acceptable for clinical decision-making. Transrectal ultrasound (TRUS) remains the most accurate bedside method (within 5–10 mL of specimen weight), with MRI providing superior accuracy (within 3–5 mL) for research purposes. CT consistently overestimates prostate volume by 15–25% due to poor soft tissue resolution. Prostate volume correlates strongly with PSA; men produce approximately 0.066 ng/mL PSA per mL of prostate tissue, forming the basis of PSA density. Prostate volume has major surgical implications: glands >80 cc have limited TURP efficacy (high retreatment rate, higher bleeding risk), and HoLEP/ThuLEP or simple prostatectomy are preferred. Conversely, UroLift is only approved for prostate volumes 30–80 cc without an obstructing median lobe. Volume-directed surgical planning has become standard practice.

Post-void residual (PVR) urine volume — the amount of urine remaining in the bladder immediately after voiding — is a key urological diagnostic parameter reflecting bladder emptying efficiency. It is measured by ultrasound (portable bladder scanner) or catheterisation; ultrasound is preferred as it is non-invasive and accurate to within 20% of catheterised volume. PVR has high test-retest variability (25–50% coefficient of variation between measurements) — a single elevated reading should always be confirmed with a second measurement. Clinically, PVR <50 mL is generally considered normal; 50–100 mL is borderline; 100–300 mL indicates voiding dysfunction requiring investigation; >300 mL may represent chronic urinary retention with risk to upper tract function. The clinical significance of PVR is context-dependent. A PVR of 150 mL in a young woman with recurrent UTIs has different implications than the same value in an 80-year-old man with BPH. In neurogenic bladder, PVR >100 mL is associated with significantly increased UTI risk and upper tract damage. In BPH, PVR >300 mL with bilateral hydronephrosis constitutes high-pressure chronic retention, requiring urgent decompression to prevent irreversible renal damage.

The Harris Hip Score (HHS) was published in 1969 by William H. Harris as the first validated clinical scoring system for hip function after acetabular fracture treatment. It rapidly became the global standard outcome measure for total hip arthroplasty (THA) and continues as the most widely cited hip outcome tool in the orthopaedic literature, despite its age and acknowledged limitations. The HHS covers four domains: pain (44 points — most weighted, reflecting its clinical importance), function (47 points — comprising gait sub-scores and activity sub-scores), deformity (4 points), and range of motion (5 points). The total score of 100 represents normal hip function. Scores ≥90 are considered excellent, 80–89 good, 70–79 fair, and <70 poor. The minimum clinically important difference (MCID) for the HHS is approximately 11 points — a change of this magnitude represents a meaningful improvement from the patient's perspective. Importantly, the HHS is a clinician-administered score combining patient-reported and objective components, making it sensitive to both subjective experience and functional examination findings. It has been validated across hip arthroplasty, hip fracture, and avascular necrosis populations.

The Oxford Knee Score (OKS) was developed in 1998 at the University of Oxford specifically to evaluate patient outcomes after total knee replacement (TKR). Unlike clinician-administered scores (e.g., Knee Society Score), the OKS is entirely patient-reported, making it free from examiner bias and particularly suited for large-scale outcome monitoring. It was adopted by the National Joint Registry (UK) as the mandatory outcome tool for all knee arthroplasty procedures, generating one of the world's largest outcomes datasets. The 2011 revised OKS uses a 0–48 scoring system (12 questions × 0–4 each), where 48 represents perfect knee function. The original 1998 version used a 12–60 scale — caution is needed when comparing across studies to confirm which version is used. The four performance bands (satisfactory 40–48, mild–moderate 30–39, moderate–severe 20–29, severe 0–19) provide intuitive clinical thresholds for outcome assessment and arthroplasty referral decisions. The minimum clinically important difference (MCID) for the OKS is 5 points, and an MCID of 15 points is considered a "substantial clinical benefit" following arthroplasty. Patient satisfaction after TKR is strongly correlated with post-operative OKS — patients achieving >34 at 12 months have >90% likelihood of reporting satisfaction with surgery.

The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a comprehensive 30-item patient-reported outcome measure for upper extremity disability. The QuickDASH, developed in 2005, is an abbreviated 11-item version that preserves the psychometric properties of the full DASH while dramatically reducing respondent burden. Both tools evaluate difficulty performing activities and symptoms (pain, tingling, weakness) over the preceding week. The QuickDASH has become the most widely used upper extremity outcome tool in clinical practice and research, adopted by sports medicine, hand surgery, shoulder surgery, and occupational medicine. It covers the full spectrum of upper limb conditions: rotator cuff disease, frozen shoulder, carpal tunnel syndrome, lateral epicondylitis, fractures, nerve injuries, and arthroplasty. The score ranges 0–100, where 0 represents no disability. The MCID (minimal clinically important difference) for the QuickDASH is approximately 15.9 points — a change of this magnitude reflects a meaningful clinical improvement from the patient's perspective. The tool is particularly sensitive to detecting post-treatment change and is reliable in both research and clinical audit settings.

The Constant-Murley Score (CMS) was published in 1987 as the first standardised shoulder function assessment combining subjective patient-reported outcomes with objective clinical examination. It has since become the most widely used shoulder outcome measure in Europe and is endorsed by the European Shoulder and Elbow Society (ESES). The CMS evaluates four domains: pain (15 pts), activities of daily living (20 pts), range of motion (40 pts), and abduction strength (25 pts). The high weighting of ROM (40%) and strength (25%) gives the CMS greater sensitivity to objective functional deficits compared to purely patient-reported tools. Strength is measured using a spring balance or isokinetic dynamometer at 90° abduction — the most technically demanding component, with significant inter-observer variability. The age- and sex-adjusted CMS corrects for normative differences, allowing fairer comparison across demographic groups. An adjusted score <70% is considered abnormal. The MCID is approximately 10–12 points. The tool is particularly valuable for evaluating rotator cuff repair outcomes, reverse shoulder arthroplasty, and SLAP repair — where objective ROM and strength restoration are primary surgical goals.

The Mangled Extremity Severity Score (MESS) was developed in 1990 to provide an objective, reproducible score to guide the difficult clinical decision between limb salvage and primary amputation in severe lower extremity trauma. The four scored domains reflect the key determinants of limb viability: skeletal and soft tissue destruction (1–4 points), degree of limb ischaemia (1–3 points, doubled if present >6 hours), haemodynamic shock (0–2 points), and patient age (0–2 points). A MESS score ≥7 was originally associated with 100% sensitivity for predicting eventual amputation in the derivation cohort. However, subsequent validation studies have demonstrated significant limitations — particularly low specificity (~46%), meaning many limbs with MESS ≥7 are successfully salvaged with modern techniques. The MESS is best used as one component of a comprehensive clinical assessment, alongside other tools such as the NISSSA (Nerve Injury, Ischaemia, Soft Tissue injury, Skeletal injury, Shock, and Age of patient score) and clinical judgement. Key biological determinants of salvage outcome include warm ischaemia time (>6 hours dramatically worsens outcomes), plantar sensation (its absence is the strongest single predictor of failed salvage), and the zone of injury extent. Modern free-flap microsurgery and endovascular techniques have improved salvage rates beyond what historical data suggested.

Acute compartment syndrome (ACS) is a limb-threatening and potentially life-threatening emergency caused by elevated pressure within a closed fascial compartment, leading to tissue perfusion failure and ischaemic necrosis. ACS most commonly occurs after tibial shaft fractures (~10%), distal radius fractures (~1%), and crushing injuries, but can follow any cause of compartment volume increase or external compression. The pathophysiological mechanism involves a vicious cycle: increased compartment pressure reduces arteriovenous pressure gradient → decreased capillary perfusion → ischaemia → oedema → further pressure increase. Cell death begins within 4–6 hours of sustained ischaemia, with irreversible Volkmann contracture developing after 8–12 hours. Two thresholds are used clinically: absolute compartment pressure ≥30 mmHg (Whiteside threshold) and delta pressure (ΔP = diastolic BP − compartment pressure) <30 mmHg (McQueen threshold). The ΔP approach is preferred because it accounts for individual perfusion pressure — a patient with low diastolic BP is at risk at lower absolute compartment pressures. Continuous compartment pressure monitoring via slit catheter is the gold standard for unconscious or intubated patients where clinical assessment is impossible.

Venous thromboembolism (VTE) — comprising deep vein thrombosis (DVT) and pulmonary embolism (PE) — is the most common preventable cause of hospital death in surgical patients. Without prophylaxis, symptomatic DVT rates following major lower limb orthopaedic surgery reach 15–40% for DVT and 1–3% for PE. The Caprini score was developed in 2005 to provide a validated, reproducible risk stratification tool guiding the choice and intensity of thromboprophylaxis. The Caprini model assigns weighted scores to clinical risk factors based on their relative contribution to thrombotic risk. Major orthopaedic procedures (THA, TKA) automatically score 5 points, reflecting their very high VTE risk and justifying extended pharmacological prophylaxis. The model identifies four risk categories (low, moderate, high, highest) with corresponding VTE event rates and prophylaxis recommendations aligned with ACCP, AAOS, and NICE guidelines. Critically, thromboprophylaxis decisions must balance VTE risk against bleeding risk. The surgeon must assess both Caprini score AND haemorrhage risk factors (prior bleeding, thrombocytopenia, spinal anaesthesia, reoperation in contaminated field) before prescribing pharmacological agents. For most elective major orthopaedic procedures, direct oral anticoagulants (DOACs — rivaroxaban, apixaban, dabigatran) have replaced LMWH as the preferred extended prophylaxis agents.

The Neck Disability Index (NDI) was developed in 1991 as the first disease-specific disability instrument for neck pain, adapted from the Oswestry Disability Index for the cervical spine. It is currently the most widely used and cited patient-reported outcome measure for cervical spine conditions in clinical practice and research worldwide. The NDI comprises 10 sections covering pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation. Each section is scored 0–5 (0 = no disability, 5 = complete disability), giving a maximum raw score of 50. This is expressed as a percentage by multiplying by 2. The five clinical disability bands (no disability 0–8%, mild 10–28%, moderate 30–48%, severe 50–64%, complete 66–100%) guide clinical decision-making and communication. The NDI demonstrates excellent test-retest reliability (ICC 0.89–0.99), good convergent validity with pain VAS and SF-36, and strong responsiveness to treatment change. The minimum clinically important difference (MCID) is 7.5–15% depending on the population and context. The NDI is sensitive to cervical radiculopathy, myelopathy, whiplash-associated disorders, and post-surgical cervical spine outcomes.

The Oswestry Disability Index (ODI) has been the gold-standard patient-reported outcome measure for low back pain and lumbar spine conditions since its introduction in 1980. It was designed to quantify the impact of back pain on everyday functioning, addressing limitations of the visual analogue scale which captures pain intensity but not functional disability. The ODI was derived from clinical assessment by John O'Brien and colleagues at Oswestry, Shropshire, and first published by Fairbank et al. in 1980. The revised ODI version 2.0 (2000) includes 10 sections: pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and travelling. Each section is scored 0–5 (0 = no disability, 5 = maximal disability), with total score expressed as a percentage (total/50 × 100). The five clinical bands guide management pathways: minimal (0–20%), moderate (21–40%), severe (41–60%), crippled (61–80%), and bed-bound/exaggerated (81–100%). The ODI has been validated across acute and chronic LBP, lumbar disc herniation, spinal stenosis, spondylolisthesis, and post-surgical populations. The MCID is 10 percentage points, and a substantial clinical benefit threshold of 20% is used in surgical outcome research. The ODI correlates highly with the SF-36 physical component score and Roland-Morris Disability Questionnaire.